O	0	4	Dose
O	4	5	-
O	5	10	dense
O	11	19	biweekly
B-intervention	20	31	doxorubicin
I-intervention	31	32	/
I-intervention	32	41	docetaxel
O	42	48	versus
B-control	49	59	sequential
I-control	60	71	neoadjuvant
I-control	72	84	chemotherapy
O	85	89	with
O	90	101	doxorubicin
O	101	102	/
O	102	118	cyclophosphamide
O	118	119	/
O	119	128	docetaxel
O	129	131	in
B-eligibility	132	140	operable
I-eligibility	141	147	breast
I-eligibility	148	154	cancer
O	154	155	:
O	156	162	second
O	163	170	interim
O	171	179	analysis
O	179	180	.

O	181	187	Timing
O	188	190	of
O	191	199	systemic
O	200	209	treatment
O	210	212	in
O	213	220	primary
O	221	229	operable
O	230	236	breast
O	237	243	cancer
O	244	246	is
O	247	254	subject
O	255	257	to
O	258	267	extensive
O	268	281	investigation
O	281	282	,
O	283	293	suggesting
O	294	298	that
O	299	309	pathologic
O	310	318	complete
O	319	328	remission
O	329	330	(
O	330	333	pCR
O	333	334	)
O	335	340	might
O	341	348	improve
O	349	357	survival
O	358	360	in
O	361	365	this
O	366	373	setting
O	373	374	.

O	375	378	The
O	379	385	German
O	386	394	Adjuvant
O	395	401	Breast
O	402	408	Cancer
O	409	414	Group
O	415	425	previously
O	426	438	demonstrated
O	439	442	the
O	443	454	feasibility
O	455	457	of
O	458	459	a
O	460	464	dose
O	464	465	-
O	465	470	dense
O	471	479	biweekly
O	480	488	schedule
O	489	491	of
O	492	493	4
O	494	500	cycles
O	501	512	doxorubicin
O	513	515	50
O	516	518	mg
O	518	519	/
O	519	521	m2
O	522	525	and
O	526	535	docetaxel
O	536	538	75
O	539	541	mg
O	541	542	/
O	542	544	m2
O	545	546	(
O	546	550	ddAT
O	550	551	)
O	552	553	+
O	553	554	/
O	554	555	-
O	556	565	tamoxifen
O	566	568	in
O	569	572	the
O	573	584	neoadjuvant
O	585	592	setting
O	593	595	to
O	596	601	yield
O	602	603	a
O	604	607	pCR
O	608	610	of
O	611	612	9
O	612	613	.
O	613	614	7
O	614	615	%
O	616	617	(
O	617	624	Gepardo
O	625	630	trial
O	630	631	)
O	631	632	.

O	633	641	Patients
O	642	650	assigned
O	651	653	to
O	654	658	ddAT
O	659	667	received
O	668	680	prophylactic
O	681	692	granulocyte
O	693	699	colony
O	699	700	-
O	700	711	stimulating
O	712	718	factor
O	719	726	support
O	727	728	(
O	728	729	5
O	730	735	micro
O	736	737	g
O	737	738	/
O	738	740	kg
O	741	745	days
O	746	747	5
O	747	748	-
O	748	750	10
O	750	751	)
O	751	752	.

O	753	756	The
O	757	764	current
O	765	770	study
O	771	772	(
O	772	780	GeparDUO
O	780	781	)
O	782	785	was
O	786	794	designed
O	795	797	to
O	798	804	assess
O	805	812	whether
O	813	816	the
O	817	820	pCR
O	821	825	rate
O	825	826	,
O	827	836	including
O	837	839	no
O	840	846	viable
O	847	855	invasive
O	856	859	and
O	860	871	preinvasive
O	872	877	tumor
O	878	883	cells
O	883	884	,
O	885	893	achieved
O	894	898	with
O	899	903	ddAT
O	904	907	was
O	908	918	equivalent
O	919	921	to
O	922	932	sequential
O	933	947	administration
O	948	950	of
O	951	962	doxorubicin
O	962	963	/
O	963	979	cyclophosphamide
O	980	988	followed
O	989	991	by
O	992	1001	docetaxel
O	1002	1003	(
O	1003	1005	AC
O	1005	1006	-
O	1006	1009	DOC
O	1009	1010	)
O	1011	1015	over
O	1016	1018	24
O	1019	1024	weeks
O	1025	1027	in
O	1028	1035	primary
O	1036	1044	operable
O	1045	1051	breast
O	1052	1058	cancer
O	1058	1059	.

O	1060	1064	From
O	1065	1069	June
O	1070	1074	1999
O	1075	1077	to
O	1078	1087	September
O	1088	1092	2001
O	1092	1093	,
B-total-participants	1094	1097	913
O	1098	1106	patients
O	1107	1111	were
O	1112	1120	enrolled
O	1121	1123	in
O	1124	1128	this
O	1129	1134	trial
O	1134	1135	.

O	1136	1138	In
O	1139	1144	total
O	1144	1145	,
B-total-participants	1146	1149	395
O	1150	1158	patients
O	1159	1169	randomized
O	1170	1176	before
O	1177	1183	August
O	1184	1185	1
O	1185	1186	,
O	1187	1191	2000
O	1191	1192	,
O	1193	1197	were
O	1198	1206	included
O	1207	1209	in
O	1210	1213	the
O	1214	1220	second
O	1221	1228	interim
O	1229	1237	analysis
O	1237	1238	.

O	1239	1245	Safety
O	1246	1250	data
O	1251	1255	were
O	1256	1265	available
O	1266	1270	from
B-total-participants	1271	1274	369
O	1275	1283	patients
O	1284	1285	(
O	1285	1289	ddAT
O	1289	1290	,
O	1291	1292	n
O	1293	1294	=
B-intervention-participants	1295	1298	191
O	1298	1299	;
O	1300	1302	AC
O	1302	1303	-
O	1303	1306	DOC
O	1306	1307	,
O	1308	1309	n
O	1310	1311	=
B-control-participants	1312	1315	178
O	1315	1316	)
O	1317	1330	demonstrating
O	1331	1335	that
O	1336	1344	toxicity
O	1345	1347	of
O	1348	1352	both
O	1353	1361	regimens
O	1362	1365	was
O	1366	1375	tolerable
O	1375	1376	.

B-outcome	1377	1382	Grade
I-outcome	1383	1384	3
I-outcome	1384	1385	/
I-outcome	1385	1386	4
I-outcome	1387	1398	neutropenia
O	1399	1407	occurred
O	1408	1410	in
B-iv-bin-percent	1411	1413	39
I-iv-bin-percent	1413	1414	.
I-iv-bin-percent	1414	1415	8
I-iv-bin-percent	1415	1416	%
O	1417	1419	of
O	1420	1428	patients
O	1429	1438	receiving
O	1439	1443	ddAT
O	1444	1447	and
O	1448	1450	in
B-cv-bin-percent	1451	1453	69
I-cv-bin-percent	1453	1454	.
I-cv-bin-percent	1454	1455	3
I-cv-bin-percent	1455	1456	%
O	1457	1459	of
O	1460	1468	patients
O	1469	1476	treated
O	1477	1481	with
O	1482	1484	AC
O	1484	1485	-
O	1485	1488	DOC
O	1488	1489	.

O	1490	1498	Efficacy
O	1499	1503	data
O	1504	1508	were
O	1509	1518	available
O	1519	1521	in
B-total-participants	1522	1525	378
O	1526	1534	patients
O	1534	1535	.

O	1536	1537	A
B-outcome	1538	1541	pCR
I-outcome	1542	1550	occurred
O	1551	1553	in
O	1554	1556	14
O	1556	1557	.
O	1557	1558	8
O	1558	1559	%
O	1560	1562	of
O	1563	1566	the
O	1567	1574	primary
O	1575	1581	breast
O	1582	1588	tumors
O	1588	1589	.

O	1590	1599	According
O	1600	1602	to
O	1603	1606	the
O	1607	1622	recommendations
O	1623	1625	of
O	1626	1629	the
O	1630	1634	data
O	1635	1645	monitoring
O	1646	1655	committee
O	1655	1656	,
O	1657	1668	recruitment
O	1669	1671	to
O	1672	1675	the
O	1676	1681	study
O	1682	1685	was
O	1686	1692	halted
O	1693	1695	as
O	1696	1698	of
O	1699	1708	September
O	1709	1713	2001
O	1714	1715	(
O	1715	1716	n
O	1717	1718	=
O	1719	1722	913
O	1722	1723	/
O	1723	1727	1000
O	1727	1728	)
O	1729	1732	due
O	1733	1735	to
O	1736	1739	the
O	1740	1751	significant
O	1752	1762	difference
O	1763	1765	in
O	1766	1769	pCR
O	1770	1775	rates
O	1776	1784	observed
O	1785	1792	between
O	1793	1796	the
O	1797	1806	treatment
O	1807	1811	arms
O	1811	1812	.

O	1813	1820	Surgery
O	1821	1824	was
O	1825	1835	documented
O	1836	1838	in
O	1839	1842	380
O	1843	1851	patients
O	1851	1852	.

B-outcome	1853	1859	Breast
I-outcome	1860	1872	conservation
O	1873	1876	was
O	1877	1885	possible
O	1886	1888	in
O	1889	1892	288
O	1893	1898	cases
O	1899	1900	(
O	1900	1902	75
O	1902	1903	.
O	1903	1904	8
O	1904	1905	%
O	1905	1906	)
O	1906	1907	.

O	1908	1911	The
O	1912	1923	application
O	1924	1926	of
O	1927	1931	both
O	1932	1941	schedules
O	1942	1944	is
O	1945	1949	safe
O	1950	1953	and
O	1954	1962	feasible
O	1963	1965	in
O	1966	1968	an
O	1969	1979	outpatient
O	1980	1987	setting
O	1987	1988	.

O	1989	1997	Although
O	1997	1998	,
O	1999	2006	results
O	2007	2015	obtained
O	2016	2020	from
O	2021	2025	this
O	2026	2033	interim
O	2034	2042	analysis
O	2043	2046	are
O	2047	2058	encouraging
O	2058	2059	,
O	2060	2067	caution
O	2068	2070	is
O	2071	2082	recommended
O	2083	2088	until
O	2089	2092	the
O	2093	2100	results
O	2101	2109	obtained
O	2110	2114	show
O	2115	2126	statistical
O	2127	2137	difference
O	2138	2140	in
O	2141	2144	pCR
O	2144	2145	.
